Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum

• DOI: 10.3346/jkms.2020.35.e361
• Publication Date: 2020-10-13T04:13:39Z
• Authors: Jongmin Lee; Hyemin Jang; Sung Hoon Kang; Jaeho Kim; Ji Sun Kim; Jun Pyo Kim; Hee Jin Kim; Sang Won Seo; Duk L. Na
• Keywords: Male; Amyloid beta-Peptides; tau Proteins; Middle Aged; Severity of Illness Index; Peptide Fragments; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; ROC Curve; Alzheimer Disease; Area Under Curve; Case-Control Studies; Positron-Emission Tomography; Humans; Original Article; Cognitive Dysfunction; Female; Biomarkers; Aged

Background Cerebrospinal fluid (CSF) biomarkers are increasingly used in clinical practice for the diagnosis of Alzheimer's disease (AD). We aimed to 1) determine cutoff values CSF AD, 2) investigate their utility by estimating a concordance with amyloid positron emission tomography (PET), and 3) apply ATN (amyloid/tau/neurodegeneration) classification based on results. Methods performed analysis 51 normal controls (NC), 23 mild cognitive impairment (MCI) 65 AD dementia (ADD) patients at Samsung Medical Center Korea. attempted develop differentiating ADD from NC using receiver operating characteristic analysis. also investigated between PET results applied scheme biomarker abnormalities characterize our participants. Results Aβ42, total tau (t-tau) phosphorylated (p-tau) significantly differed across three groups. The area under curve differentiation was highest t-tau/Aβ42 (0.994) followed p-tau/Aβ42 (0.963), Aβ42 (0.960), t-tau (0.918), p-tau (0.684). rate 92%. Finally, led majority categorized into A-T-N-(73%), MCI as A+T-N-(30%)/A+T+N+(26%), A+T+N+(57%). Conclusion had high sensitivity specificity were accurate PET. subtypes may further serve predict prognosis.